Navigation Links
Transgenomic Announces Partnership With Key Genomics for Ovarian Cancer Assay to Guide Therapeutic Options
Date:9/16/2008

intended to provide the optimal therapy recommendation according to the molecular characteristics of each patient's tumor.

Tim Gallagher, Key Genomics CEO, said, "An algorithm that could quickly sort molecular information about a patient's particular tumor, and then match this information with the right drug treatment would be a valuable medical breakthrough. COXEN has the potential to bring significant healthcare and economic value by personalizing cancer therapy by using such a method, an algorithm based on in vitro response to anti-cancer drugs."

References

1. National Cancer Institute web site: http://www.cancer.gov/cancertopics/types/ovarian/

2. Lee JK et al. A strategy for predicting the chemosensitivity of human cancers and its application to drug discovery. Proc Natl Acad Sci U S A. 2007 Aug 7;104(32):13086-91. Epub 2007 Jul 31.

About Transgenomic

Transgenomic is a global biotechnology company that provides unique products and services of automated high sensitivity genetic variation and mutation analysis. Their offerings include systems, products, discovery and laboratory testing services to the academic and medical research, clinical laboratory and pharmaceutical markets in the fields of Pharmacogenomics and personalized medicine. Specific offerings include WAVE(R) DHPLC Systems, related consumables and assay kits, Cytogenetics automated systems, and Transgenomic Pharmacogenomics and Reference Laboratory Services. Transgenomic Pharmacogenomics and Laboratory Services utilize their technology and expertise to provide a menu of mutation scanning tests for over 700 cancer-associated genes and more than 60 validated diagnostic tests to meet the needs of pharmaceutical and biotech companies, research and clinical laboratories, physicians and patients. For more information about the innovative systems, products and services offered by Tr
'/>"/>

SOURCE Transgenomic
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. Transgenomic Reports Second Quarter 2008 Results
2. Reminder: Webcast Alert: Transgenomic Inc. Announces Second Quarter 2008 Earnings Release Conference Call Webcast
3. Webcast Alert: Transgenomic Inc. Announces Second Quarter 2008 Earnings Release Conference Call Webcast
4. Transgenomic Introduces SURVEYOR(R) Endonuclease Adaptor-Ligated Libraries (SEAL) for Determining Whole Genome Sequence Variation
5. Webcast Alert: Transgenomic Inc. Announces First Quarter 2008 Earnings Release Conference Call Webcast
6. Transgenomic Opens Pharmacogenomics Laboratory in China
7. Reminder Webcast Alert: Transgenomic Inc. Announces Fourth Quarter 2007 Earnings Release Conference Call Webcast
8. Webcast Alert: Transgenomic Inc. Announces Fourth Quarter 2007 Earnings Release Conference Call Webcast
9. Transgenomic Appoints David Pauluzzi to Board of Directors
10. Transgenomic, Inc. Forms Scientific Advisory Board
11. Webcast Alert: Transgenomic Inc. Announces Third Quarter 2007 Earnings Release Conference Call Webcast
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/22/2014)... VANCOUVER , Dec. 22, 2014 /PRNewswire/ - RepliCel ... stage regenerative medicine company focused on the development of ... paper out of the University of Calgary in conjunction ... North Carolina, which further validates the company,s ongoing clinical ... the effects of pattern baldness. The paper ...
(Date:12/22/2014)... (PRWEB) December 22, 2014 ... peer-reviewed publication of original research, reviews and editorials ... and clinical practice, today published a provocative article ... the development, progression and potential treatment of prostate ... endocrinology research and proposes the possibility that there ...
(Date:12/19/2014)... MA (PRWEB) December 19, 2014 Charm ... MRLAFMQ test for the Detection of Aflatoxin M1 in ... to receive independent third party validation. The peer reviewed ... Unit of the Institute for Agricultural and Fisheries Research ... Group. , Aflatoxin B1, the most toxic aflatoxin ...
(Date:12/19/2014)... , Dec. 19, 2014 Bina Technologies, Inc. ... announced today that they have been acquired by Roche ... is a privately held company that provides a big ... generation sequencing (NGS) data for the academic and translational ... Sequencing Unit, and will continue to focus on development ...
Breaking Biology Technology:Newly Released Peer-Reviewed Publication Further Validates RepliCel's Use of Dermal Sheath Cup Cells to Treat Pattern Baldness 2Newly Released Peer-Reviewed Publication Further Validates RepliCel's Use of Dermal Sheath Cup Cells to Treat Pattern Baldness 3Newly Released Peer-Reviewed Publication Further Validates RepliCel's Use of Dermal Sheath Cup Cells to Treat Pattern Baldness 4Newly Released Peer-Reviewed Publication Further Validates RepliCel's Use of Dermal Sheath Cup Cells to Treat Pattern Baldness 5Prostate Cancer Experts Dissect the Role of Follicle-stimulating Hormone in the Development, Progression and Potential Treatment of Prostate Cancer 2Prostate Cancer Experts Dissect the Role of Follicle-stimulating Hormone in the Development, Progression and Potential Treatment of Prostate Cancer 3Prostate Cancer Experts Dissect the Role of Follicle-stimulating Hormone in the Development, Progression and Potential Treatment of Prostate Cancer 4Charm Sciences Achieves Independent Validation of First 15 Minute Quantitative Screening Method for Aflatoxin M1 2Bina Technologies is acquired by Roche. 2Bina Technologies is acquired by Roche. 3
... Oct. 23 Celator Pharmaceuticals today,announced that Scott Jackson, ... Investor Forum in San Francisco. Mr. Jackson will,provide a ... programs. The presentation will be held on Wednesday, October,29, ... of the Palace Hotel., The company is also ...
... 23 Poniard,Pharmaceuticals, Inc. (Nasdaq: PARD ), ... it will hold a conference call to discuss,the ... update,including an update on the ongoing development activities ... McMahon, Ph.D., chairman and chief executive officer, Ronald ...
... recognizes excellence in ChIP, DNA methylation innovation ... Genpathway, Inc. announced today,that the company has ... American,Services in Drug Discovery Technologies Healthcare Innovation ... providing superior services for,chromatin immunoprecipitation (ChIP) and ...
Cached Biology Technology:Celator(R) Pharmaceuticals To Present at 2008 BIO Investor Forum 2Poniard Pharmaceuticals to Host Third Quarter 2008 Financial Results Conference Call on October 30 2Frost & Sullivan Awards Genpathway 2008 Healthcare Innovation Award 2Frost & Sullivan Awards Genpathway 2008 Healthcare Innovation Award 3
(Date:12/19/2014)... --  LaunchKey , the first decentralized mobile authentication and ... Things era, today announced the close of $3 million ... by Metamorphic Ventures with participation from ENIAC Ventures, Crosslink ... LaunchKey has raised $4 million to date, and will ... bring LaunchKey to market in 2015. LaunchKey ...
(Date:12/17/2014)... 2014 The Defense Logistics Agency is ... detect and prevent counterfeit microcircuits from entering into ... started performing an in-house microcircuit anti-counterfeit initiative dubbed ... of purchased microcircuits while increasing their reliability throughout ... will be conducted at DLA,s Electronics Product Test ...
(Date:12/17/2014)... Dec. 16, 2014 Valencell, a leader in ... biometric technology to industry leaders such as Intel, Jabra, ... validated, biometric wearable products. These products will be showcased ... Las Vegas . "Our ... flexible and robust – with the clinical data to ...
Breaking Biology News(10 mins):LaunchKey Raises $3 Million in Additional Funding Led by Metamorphic Ventures 2LaunchKey Raises $3 Million in Additional Funding Led by Metamorphic Ventures 3Defense Logistics Agency Launches DNA Marking Capability to Strengthen Microcircuit Supply Chain 2Defense Logistics Agency Launches DNA Marking Capability to Strengthen Microcircuit Supply Chain 3Valencell PerformTek Biometrics Power the Most Accurate Wearables at CES 2015 2
... New discoveries by researchers at the University ... a first-ever pharmacological treatment for cocaine addiction. ... to treat people with hypertension and anxiety, has ... from retrieving memories associated with cocaine use in ...
... , STONY BROOK, NY"Trophic Downgrading of Planet Earth," a review ... the journal Science, concludes that the decline of ... is causing substantial changes to Earth,s terrestrial, freshwater, and marine ... from ecosystems "may be humankind,s most pervasive influence on nature." ...
... achieved a pivotal breakthrough in the development of a cable ... possible. Armchair quantum wire (AQW) will be a weave ... over long distances. It will be an ideal replacement for ... 5 percent per 100 miles of transmission, said Rice chemist ...
Cached Biology News:UWM research offers hope for treatment of cocaine addiction 2Loss of top animal predators has massive ecological effects 2Loss of top animal predators has massive ecological effects 3'Amplified' nanotubes may power the future 2'Amplified' nanotubes may power the future 3
... Competitor Assay Kits are ideal for ... binding compounds using fluorescence polarization (FP) ... of glutathione transferase to the ligand ... [PR-LBD(GST)] and a proprietary, fluorescently-tagged progesterone ...
... vectors combine the proven features of the ... and provides all of the benefits and ... vector backbone. The pTriEx vectors have been ... genes in all three expression systems. In ...
Rabbit polyclonal to Shigella Immunogen: Mixture of S. boydii, S. flexneri & S. dysenteriae....
... Cell Identification Kit. ALDEFLUORs ... substrate for the enzyme ... is highly expressed in ... making ALDH an extremely ...
Biology Products: